In patients with previously treated FGFR2 fusion- or rearrangement-positiven ICC, the use of futibatinib provided a significant clinical benefit, with a total of 43 of 103 patients (42%; 95% confidence interval 32–52) responding, with a median PFS of 9.0 months and OS of 21.7 months [128]. The gene discussed is FGFR2; the disease is intrahepatic cholangiocarcinoma.